
|Articles|June 1, 2001
- Pharmaceutical Executive-06-01-2001
- Volume 0
- Issue 0
Rx-to-OTC: Unwanted Attention
Author(s)Kevin Gopal
Washington, DC-An FDA advisory committee voted overwhelmingly to recommend that Claritin (loratadine), Allegra (fexofenadine), and Zyrtec (cetirizine) be changed from prescription to over-the-counter products. Although the vote is not binding, FDA usually follows such panels’ recommendations.
Advertisement
Articles in this issue
almost 25 years ago
Industry Under Investigationalmost 25 years ago
Emotion - The New Brand Integratoralmost 25 years ago
For Love of the Gamealmost 25 years ago
Field of Dreamsalmost 25 years ago
Workshop: Access Optionsalmost 25 years ago
Emotion - The New Brand Integratoralmost 25 years ago
Emotion - Biotech Renaissance Manalmost 25 years ago
Relocation: Coming to Americaalmost 25 years ago
Stocks: Catching the Market Bluesalmost 25 years ago
Gathering LightNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Asembia ASX26: Adjusting Strategies to Adapt to an Uncertain Global Political and Regulatory Market
2
Which Supply Chains are Most Exposed by Disruptions in The Strait of Hormuz?
3
Asembia AXS26 Summit: The Future of High-Cost Specialty Drugs
4
Pharmaceutical Executive Daily: FDA Approves Breztri
5




